CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...